论文部分内容阅读
目的 探讨普伐他汀对冠心病患者血脂及血管内皮功能的影响。方法 测定 32例冠心病患者 (治疗组 )降脂治疗 (普伐他汀 10mg ,每晚 1次 ,疗程 8周 )前后及 30例健康人 (对照组 )血清总胆固醇(TC)、低密度脂蛋白 (LDL C)、高密度脂蛋白 (HDL C)、甘油三酯 (TG)、血浆内皮素 (ET)、一氧化氮 (NO)的变化。结果 血浆ET在冠心病组显著高于对照组 ,而NO显著低于对照组 ;冠心病组降脂治疗 8周后 ,ET明显下降 (P <0 .0 1) ,NO明显升高 (P <0 .0 1) ,血TC、LDL C、TG明显降低 (P <0 .0 1,P <0 .0 5 ) ,HDL C亦升高 ,但无统计学意义。结论 冠心病患者普伐他汀调脂治疗的同时 ,可显著改善血管内皮细胞功能。
Objective To investigate the effect of pravastatin on blood lipid and endothelial function in patients with coronary heart disease. Methods The levels of total cholesterol (TC), low density lipoprotein (LDL) and total cholesterol in 30 healthy people (control group) were measured before and after treatment with lipid lowering therapy (pravastatin 10 mg, once a night, for 8 weeks) (LDL C), high density lipoprotein (HDL C), triglyceride (TG), plasma endothelin (ET) and nitric oxide (NO) Results Plasma ET was significantly higher in CHD group than in control group, while NO was significantly lower than that in control group. ET decreased significantly (P <0.01) 0. 01), blood TC, LDL C and TG were significantly lower (P <0.01, P <0.05), HDL C also increased, but not statistically significant. Conclusion Coronary heart disease patients pravastatin lipid-lowering treatment at the same time, can significantly improve endothelial cell function.